Importantly, the high sRANKL/OPG ratio is a negative predictor of survival in MM (20, 98) and ist therapeutic targeting with Denosumab, an anti-RANKL antibody, has been shown to reduce osteoclastogenesis and bone resorption markers in MM patients (99). This evidence concerns the gene TNFSF11 and Miyoshi myopathy.